AEM vs BON

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

The company exhibits weak fundamental health with a Piotroski F-Score of 6/9, indicating borderline stability, and lacks an Altman Z-Score, raising concerns about financial distress risk. Despite trading at a steep discount to the Graham Number ($337.95 vs. current price of $1.70), the business shows deteriorating fundamentals, including a -21.90% YoY revenue decline and minimal profitability. Negative long-term price performance (-99.9% over 5 years) and absence of analyst coverage further signal investor abandonment. While balance sheet metrics appear healthy, the lack of growth, cash flow data, and earnings visibility undermines any value proposition.